![Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort - Gros - 2023 - United European Gastroenterology Journal - Wiley Online Library Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort - Gros - 2023 - United European Gastroenterology Journal - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/0292b61c-854e-40a1-8b32-78b194b48d19/ueg212357-toc-0001-m.jpg)
Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort - Gros - 2023 - United European Gastroenterology Journal - Wiley Online Library
![ADVANZ PHARMA enters into an exclusive agreement with Alvotech to commercialise a proposed biosimilar to Xolair® (omalizumab) | ADVANZ PHARMA ADVANZ PHARMA enters into an exclusive agreement with Alvotech to commercialise a proposed biosimilar to Xolair® (omalizumab) | ADVANZ PHARMA](https://www.advanzpharma.com/media/uploads/_largeCrop/ADVANZ-PHARMA-enters-into-an-exclusive-agreement-with-Alvotech.jpg)
ADVANZ PHARMA enters into an exclusive agreement with Alvotech to commercialise a proposed biosimilar to Xolair® (omalizumab) | ADVANZ PHARMA
![Literature review of international biosimilar medicines update – December 2016 to March 2017 | Australian Government Department of Health and Aged Care Literature review of international biosimilar medicines update – December 2016 to March 2017 | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/images/publications/2022/05/literature-review-of-international-biosimilar-medicines-update-december-2016-to-march-2017.png)
Literature review of international biosimilar medicines update – December 2016 to March 2017 | Australian Government Department of Health and Aged Care
![Tocilizumab biosimilar successfully meets primary, secondary endpoints in Phase I study: Dr Reddy's Labs Tocilizumab biosimilar successfully meets primary, secondary endpoints in Phase I study: Dr Reddy's Labs](https://medicaldialogues.in/h-upload/2022/10/20/188658-dr-reddy-new.webp)
Tocilizumab biosimilar successfully meets primary, secondary endpoints in Phase I study: Dr Reddy's Labs
![dr reddy: Dr Reddy's completes clinical studies of its proposed rituximab biosimilar candidate - The Economic Times dr reddy: Dr Reddy's completes clinical studies of its proposed rituximab biosimilar candidate - The Economic Times](https://m.economictimes.com/thumb/msid-97163997,width-1200,height-900,resizemode-4,imgsize-50790/lab.jpg)
dr reddy: Dr Reddy's completes clinical studies of its proposed rituximab biosimilar candidate - The Economic Times
![Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Care Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Care](https://cdn.slidesharecdn.com/ss_thumbnails/pvipracticeaidsbbg-200501132839-thumbnail.jpg?width=640&height=640&fit=bounds)